Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

Author(s): Costelloe L, Jones J, Coles A


Alemtuzumab is a humanized monoclonal antibody that causes prolonged lymphopenia. In a recent Phase III trial, alemtuzumab was shown to reduce both the annualized relapse rate and the rate of sustained accumulation of disability by over 70% when compared with IFN-β1a. However, the drug is associated with thyroid autoimmunity in approximately a third of treated patients, as well as other secondary autoimmune conditions in smaller numbers. Secondary autoimmunity typically arises during reconstitution of the lymphocyte repertoire. Individuals with high baseline circulating levels of IL-21 are at highest risk of developing autoimmunity following treatment with alemtuzumab.

Similar Articles

Drug-induced PML: a global agenda for a global challenge

Author(s): Vinhas de Souza M, Keller-Stanislawski B, Blake K, Hidalgo-Simon A, Arlett P, et al.

Novel therapeutic options for multiple sclerosis

Author(s): Curtin F, Hartung HP

Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments

Author(s): Achiron A, Barak Y, Gail M, Mandel M, Pee D, et al.

Managing the risks of immunosuppression

Author(s): Riminton DS, Hartung HP, Reddel SW

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

Author(s): Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, et al.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

Author(s): Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, et al.

Clinical prognostic factors in multiple sclerosis: a natural history review

Author(s): Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC